The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution

The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, with incidence rate of 4: 100 thousand per year, according to European data. CLL remains an incurable disease, with most patients over 60 years old. Immunochemotherapy schemes today remain the standard treatment approach f...

Full description

Bibliographic Details
Main Authors:	Irina V. Poddubnaya, Tatyana E. Bialik, Natalya N. Glonina, Olga B. Kalashnikova, Kamil D. Kaplanov, Valery A. Lapin, Nadezhda V. Medvedeva, Natalya B. Mikhailova, Tatyana N. Moiseeva, Evgeniy A. Nikitin, Tatyana I. Pospelova, Elena A. Stadnik
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2020-05-01
Series:	Современная онкология
Subjects:	chronic lymphocytic leukemia bruton tyrosine kinase inhibitors immunochemotherapy targeted therapy ibrutinib acalabrutinib
Online Access:	https://modernonco.orscience.ru/1815-1434/article/viewFile/34009/21719

Similar Items

Bruton’s Tyrosine Kinase Inhibitors: Recent Updates
by: Amneh Fares, et al.
Published: (2024-02-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Abdullah Mohammad Khan
Published: (2022-04-01)

The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives
by: Toby A. Eyre, et al.
Published: (2023-05-01)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
by: Skye Montoya, et al.
Published: (2023-07-01)

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
by: Zemene Demelash Kifle
Published: (2021-09-01)

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases
by: Yu. S. Torshina, et al.
Published: (2023-06-01)

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice
by: Caroline E. O'Riordan, et al.
Published: (2019-09-01)

Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
by: Brooke Benner, et al.
Published: (2021-01-01)

Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
by: Anselm Morell, et al.
Published: (2020-12-01)

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
by: Tadeusz Robak, et al.
Published: (2022-02-01)

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
by: Susan M. O’Brien, et al.
Published: (2021-11-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Obada Ababneh, et al.
Published: (2022-05-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
by: Lorenzo-Vizcaya A, et al.
Published: (2020-06-01)

Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
by: Sklavenitis-Pistofidis R., et al.
Published: (2017-06-01)

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View
by: Tambaro FP, et al.
Published: (2021-10-01)

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
by: St-Pierre F, et al.
Published: (2022-07-01)

Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury
by: Chen Guang Yu, et al.
Published: (2021-12-01)

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
by: Alexander N. R. Weber, et al.
Published: (2017-11-01)

Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations
by: Xiangfan Yu, et al.
Published: (2022-11-01)

Bruton’s tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice
by: Kazuhiko Kawata, et al.
Published: (2024-04-01)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
by: Sining Zhu, et al.
Published: (2021-10-01)

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
by: Omar Alkharabsheh, et al.
Published: (2021-02-01)

Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review
by: Jing Shen, et al.
Published: (2022-11-01)

Bruton’s tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress
by: Simantini Ghosh, et al.
Published: (2021-12-01)

Role of Bruton’s tyrosine kinase in B cells and malignancies
by: Simar Pal Singh, et al.
Published: (2018-02-01)

Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
by: Yaya Chu, et al.
Published: (2019-01-01)

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis
by: Jari M. Tuomi, et al.
Published: (2021-11-01)

Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis
by: Monia Marchetti, et al.
Published: (2022-03-01)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
by: Jia Liu, et al.
Published: (2022-09-01)

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma
by: Zhuojun Liu, et al.
Published: (2021-06-01)

X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure
by: Caroline E. O'Riordan, et al.
Published: (2020-10-01)

Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia
by: Sergey V. Nedogoda, et al.
Published: (2021-12-01)

Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
by: Leigh Naylor-Adamson, et al.
Published: (2021-11-01)

Bruton’s tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome
by: Sarah Kröller, et al.
Published: (2023-02-01)

Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
by: Lukáš Smolej, et al.
Published: (2021-06-01)

BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
by: Vincenzo Nasillo, et al.
Published: (2022-03-01)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
by: Sining Zhu, et al.
Published: (2021-08-01)

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
by: Rula Zain, et al.
Published: (2021-07-01)

Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence
by: Monia Marchetti, et al.
Published: (2022-04-01)

Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
by: Anıl Tombak, et al.
Published: (2021-12-01)